Monzon, Jose

Medical Oncology

Clinical Associate Professor

EMAIL: jose.monzon@ahs.ca

Biography

Dr. Jose Monzon, is a medical oncologist at the Tom Baker Cancer Centre and Clinical Associate Professor for the University of Calgary. Dr. Monzon completed his postgraduate medical oncology residency training at the University of British Columbia and translational fellowship training at the Canadian Cancer Trials Group. He has also completed a PhD focusing on melanoma genetics at the University of Toronto.

He is currently the TBCC Clinical Research Unit Medical Leader. He helps facilitate the conduct of clinical trials at the TBCC. With the option of clinical trials, patients are provided the hope of another possible line of treatment, while rewarding them with the knowledge that they are improving the care and lives of others. His current research interests include clinical trials in cutaneous and gastrointestinal malignancies.

Area of Focus

Summary of Research

Hogg D, Monzon JG, Ernst S, Song X, McWhirter E, Savage K, Avila A, Skinn B, Jiang J, Romeyer F, Smylie M. Safety and efficacy of combination nivolumab and ipilimumab in patients with advanced melanoma: results from the Canadian cohort of an expanded access program. Accepted: Current Oncology.
Burbidge T, Bastian B, Guo D, Li H, Morris D, Monzon JG, Leung G, Yang H, Cheng T. Association of indoor tanning exposure with age at melanoma diagnosis and BRAF V600E mutations. J Natl Cancer Inst. 2019 Nov 1;111(11):1228-1231. doi: 10.1093/jnci/djz048.
Drogemoller B, Monzon JG, Bhavsar A, Borrie A, Brooks B, Wright G, Liu G, Renouf D, Kollmannsberger C, Bedard P, Amikeng F, Amstutz U, Hildebrand C, Gunaretnam E, Critchley C, Chen Z, Brunham L, Hayden M, Ross C, Gelmon K, Carleton C. Association between SLC16A5 genetic variation and Cisplatin induced ototoxic effects in adult patients with testicular cancer. JAMA Oncology. 2017 Nov doi: 10.1001/jamaoncol.2017.0502. Co-First Author.
Monzon JG, Hay AE, McDonald GT, Pater JL, Meyer RM, Chen E, Chen BE, Dancey JE, Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. Eur J Cancer. 2015 Nov 03;51(17):2501-7. PubMed PMID: 26338195.
Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T, A phase 2 study of tremelimumab in patients with advanced uveal melanoma., Melanoma Res. 2015 Aug 03;25(4):342-7. PubMed PMID: 26050146. Co-First Author

Area Of Focus

Summary Of Research

Hogg D, Monzon JG, Ernst S, Song X, McWhirter E, Savage K, Avila A, Skinn B, Jiang J, Romeyer F, Smylie M. Safety and efficacy of combination nivolumab and ipilimumab in patients with advanced melanoma: results from the Canadian cohort of an expanded access program. Accepted: Current Oncology.
Burbidge T, Bastian B, Guo D, Li H, Morris D, Monzon JG, Leung G, Yang H, Cheng T. Association of indoor tanning exposure with age at melanoma diagnosis and BRAF V600E mutations. J Natl Cancer Inst. 2019 Nov 1;111(11):1228-1231. doi: 10.1093/jnci/djz048.
Drogemoller B, Monzon JG, Bhavsar A, Borrie A, Brooks B, Wright G, Liu G, Renouf D, Kollmannsberger C, Bedard P, Amikeng F, Amstutz U, Hildebrand C, Gunaretnam E, Critchley C, Chen Z, Brunham L, Hayden M, Ross C, Gelmon K, Carleton C. Association between SLC16A5 genetic variation and Cisplatin induced ototoxic effects in adult patients with testicular cancer. JAMA Oncology. 2017 Nov doi: 10.1001/jamaoncol.2017.0502. Co-First Author.
Monzon JG, Hay AE, McDonald GT, Pater JL, Meyer RM, Chen E, Chen BE, Dancey JE, Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. Eur J Cancer. 2015 Nov 03;51(17):2501-7. PubMed PMID: 26338195.
Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T, A phase 2 study of tremelimumab in patients with advanced uveal melanoma., Melanoma Res. 2015 Aug 03;25(4):342-7. PubMed PMID: 26050146. Co-First Author

Department of Oncology